This review compared high-dose intravenous immunoglobulin (HDIVIG) plus phototherapy with phototherapy alone. The authors concluded that addition of HDIVIG to phototherapy is an effective treatment for haemolytic disease of the newborn. The review was generally well conducted and the evidence presented supports the conclusions, although it should be noted that the number of included studies and patients was small.
Data extraction
The authors did not state how the data were extracted for the review, or how many reviewers performed the data extraction. The following information was tabulated: ABO/Rh status of the infants; the gestational age and birth weight of the infants in each treatment group; sample size; dose of HDIVIG; criteria used for exchange transfusion; and outcomes reported. Where necessary, authors were contacted for missing data.
Methods of synthesis
How were the studies combined?
The pooled relative risk (RR) and risk difference were calculated, along with 95% confidence intervals (CIs), for dichotomous data using a fixed-effect model. The pooled weighted mean differences (WMD) and 95% CIs were estimated for continuous data. The number-needed-to-treat (NNT) and 95% CI were estimated for significant findings.
How were differences between studies investigated?
Statistical heterogeneity was investigated using the chi-squared statistic and forest plots were presented. The pooled RR, risk difference and NNT were calculated separately for the number of infants with Rh disease requiring exchange transfusions.
Results of the review
Four RCTs (226 infants) were included.
The Jadad scores for study quality ranged from 1 to 3 out of a possible 5 points. There were several methodological flaws: failing to report intention-to-treat analysis; a lack of reporting when phototherapy treatment was started; and unclear criteria for late transfusion.
When compared with phototherapy alone, HDIVIG plus phototherapy significantly reduced the need for exchange transfusion (3 RCTs, 189 infants); the RR was 0.28 (95% CI: 0.17, 0.47). No significant heterogeneity was detected (P=0.58).
For infants with Rh disease (2 RCTs, 73 infants), HDIVIG treatment significantly reduced the need for exchange transfusion to a greater extent (RR 0.21, 95% CI: 0.10, 0.45). No significant heterogeneity was detected (P=0.77).
HDIVIG treatment plus phototherapy significantly reduced multiple exchange transfusions compared with phototherapy alone (3 RCTs, 198 infants); the RR was 0.22 (95% CI: 0.08, 0.61). No significant heterogeneity was detected (P=0.38).
The addition of HDIVIG treatment to phototherapy significantly reduced the length of hospital stay (2 RCTs, 153 infants); the WMD was -1.06 (95% CI: -1.65, -0.46). Significant heterogeneity was detected (P=0.042). One RCT found that both treatment groups had a longer stay than the other RCT.
The addition of HDIVIG treatment to phototherapy significantly reduced the duration of phototherapy treatment (2 RCTs, 153 infants); the WMD was 0.87 (95% CI: -1.37, -0.37). No significant heterogeneity was detected (P=0.36).
The increase in the number of infants receiving red cell transfusions for late anaemia just reached statistical significance, but the CIs were wide (3 RCTs, 189 infants); the RR was 8.0 (95% CI: 1.03, 62.2). No significant heterogeneity was detected (P=0.7).
The risk difference and NNT were also reported in the review.
